Inhibikase Therapeutics Files 10-K/A Amendment
Ticker: IKT · Form: 10-K/A · Filed: Apr 25, 2025 · CIK: 1750149
Sentiment: neutral
Topics: amendment, annual-report, sec-filing
TL;DR
Inhibikase filed an amendment to their 2024 annual report on 4/25/25. Check for updates.
AI Summary
Inhibikase Therapeutics, Inc. filed an amendment (10-K/A) on April 25, 2025, for their fiscal year ending December 31, 2024. The company, located in Atlanta, GA, is in the biological products sector. This filing is an amendment to their annual report, indicating updates or corrections to previously submitted information.
Why It Matters
This amendment provides updated or corrected information for investors and regulatory bodies regarding Inhibikase Therapeutics' financial performance and business operations for the fiscal year 2024.
Risk Assessment
Risk Level: low — This is a routine amendment to an annual report, not indicating new material adverse events.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the annual report)
- 10-K/A — Filing Type (Indicates an amendment to an annual report)
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Filer of the 10-K/A
- 2024-12-31 (date) — Fiscal year end
- 2025-04-25 (date) — Filing date of the amendment
- 3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA 30339 (address) — Company business and mailing address
- 001-39676 (company_id) — SEC file number
FAQ
What specific information is being amended in this 10-K/A filing?
The filing is an amendment (No. 1) to the annual report for the fiscal year ended December 31, 2024. Specific details of the amendments are not provided in this header information but would be within the full document.
When was this amendment filed with the SEC?
This amendment was filed on April 25, 2025.
What is the primary business of Inhibikase Therapeutics, Inc.?
Inhibikase Therapeutics, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' industry, SIC code 2836.
Where is Inhibikase Therapeutics, Inc. headquartered?
The company's business and mailing address is 3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA 30339.
What is the SEC file number for Inhibikase Therapeutics, Inc.?
The SEC file number is 001-39676.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 25, 2025 regarding Inhibikase Therapeutics, Inc. (IKT).